Allogene Therapeutics receives FDA RMAT designation for ALLO-316 in renal cell carcinoma
- ALLO-316, an AlloCAR T investigational product, received RMAT designation from the FDA for treating CD70 positive advanced or metastatic renal cell carcinoma (RCC).
- The designation is based on positive data from the Phase 1 TRAVERSE trial, which evaluated ALLO-316 in patients who failed standard RCC therapies.
- RMAT designation aims to accelerate development and review, offering early interactions with the FDA to streamline market approval.
- Allogene will present updated Phase 1 data at the Society for Immunotherapy of Cancer (SITC) annual meeting.
Read more
Novartis Scemblix FDA approved in newly diagnosed CML, offering superior efficacy, and favorable safety and tolerability profile
- Scemblix (asciminib) received accelerated FDA approval for newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP).
- Approval is based on the ASC4FIRST Phase III trial, showing superior major molecular response (MMR) rates at week 48 compared to standard of care tyrosine kinase inhibitors (TKIs).
- Scemblix demonstrated fewer treatment-related adverse reactions and dose reductions compared to other TKIs, with a favorable safety profile.
- The ASC4FIRST trial continues, with further analysis planned at week 96 to evaluate additional efficacy and safety endpoints.
Read more
Biond Biologics partners with Merck KGaA for phase 1 trial of BND-35 with cetuximab
- Biond Biologics collaborates with Merck KGaA to evaluate BND-35 with cetuximab in a Phase 1 trial for solid tumors.
- Merck KGaA will supply cetuximab for the trial, which aims to assess the safety and efficacy of the combination.
- BND-35 is an anti-ILT3 antibody designed to remodel the tumor microenvironment and enhance immune response.
- Enrollment for the BND-35 monotherapy arm has begun, with several patients already dosed.
Read more
Shorla Oncology receives FDA expanded approval for Jylamvo in pediatric indications
- The FDA has expanded the approval of Jylamvo (methotrexate) to treat pediatric patients with acute lymphoblastic leukemia (ALL) and polyarticular juvenile idiopathic arthritis (pJIA).
- Jylamvo is the only oral liquid methotrexate approved for both adult and pediatric indications, offering a convenient alternative for patients who have difficulty swallowing pills.
- The drug remains stable at room temperature for 90 days, eliminating the need for refrigeration, which adds convenience for patients.
- Next steps include ensuring the continuity of supply and expanding the portfolio of innovative therapies for underserved patient populations.
Read more
Immorta Bio's SenoVax reduces growth and stops metastasis of aggressive breast cancer
- SenoVax, an immune stimulatory therapy, successfully reduced tumor growth and metastasis in aggressive breast cancer animal models.
- The therapy works by removing senescent cells surrounding tumors, allowing the immune system to attack the cancer.
- SenoVax has shown promise in previous studies, including reducing lung cancer growth and aiding blood cell recovery post-chemotherapy.
- The data is covered by several patents, indicating potential for future clinical applications.
Read more
GlycoMimetics announces phase 2/3 study of uproleselan did not meet primary endpoint
- The Phase 2/3 study of uproleselan in combination with 7+3 chemotherapy for AML patients did not show significant improvement in event-free survival.
- The study was conducted by the National Cancer Institute and the Alliance for Clinical Trials in Oncology.
- GlycoMimetics is coordinating with the Alliance for further data analysis, including subgroup analysis for potential efficacy signals.
- Top-line results are expected to be presented by the NCI at a future medical conference.
Read more
Shuttle Pharma doses first patients in phase 2 clinical trial of ropidoxuridine for treatment of patients with glioblastoma
- Shuttle Pharmaceuticals has dosed the first three patients in its Phase 2 trial of Ropidoxuridine for glioblastoma treatment.
- The trial targets IDH wild-type, methylation negative glioblastoma patients, who currently have limited treatment options.
- 40 patients will be randomized into two dose groups to determine the optimal dose, with an additional 14 patients to be added later.
- The trial aims to complete within 18 to 24 months, focusing on survival compared to historical controls.
Read more
Immunome presents compelling preclinical data demonstrating robust anti-tumor activity for IM-1021
- Immunome presented preclinical data for IM-1021, a ROR1-targeted ADC, at the EORTC-NCI-AACR Symposium.
- IM-1021 showed superior efficacy in mantle cell lymphoma and triple negative breast cancer models.
- The ADC payload HC74 demonstrated higher potency and better ADME properties compared to deruxtecan.
- Immunome plans to submit an IND for IM-1021 to the FDA in Q1 2025, aiming to start clinical trials post-clearance.
Read more
theMednet awarded $2M contract by the National Cancer Institute to develop AI-based platform
- theMednet received a $2 million contract from the National Cancer Institute to create an AI platform for clinical trial searches.
- The platform aims to enhance physician engagement and improve diversity in clinical trial participation.
- It will use AI to match physician inquiries with relevant trials, offering real-time, personalized recommendations.
- The project is funded by the National Cancer Institute, part of the National Institutes of Health.
Read more
MilliporeSigma invests $76 million to expand ADC manufacturing for novel cancer therapies
- MilliporeSigma is investing $76 million to expand its ADC manufacturing capabilities in St. Louis, Missouri.
- The expansion will triple existing capacity, enhancing support for early-stage and commercial bioconjugates.
- The project includes upgrading 34,000 square feet for various departments and adding new labs and storage facilities.
- This investment aims to accelerate the development and delivery of novel cancer therapies.
Read more
Phase III results for Genentech’s Itovebi show significant progression-free survival in HR-positive advanced breast cancer
- Genentech's Itovebi, combined with palbociclib and fulvestrant, shows a 57% reduction in disease progression risk in HR-positive, HER2-negative breast cancer.
- The Phase III INAVO120 study results published in the New England Journal of Medicine highlight a progression-free survival of 15.0 months versus 7.3 months for the control group.
- The FDA has approved Itovebi for use in specific breast cancer cases, and submissions are underway for approval by other global health authorities.
- Itovebi is being further investigated in additional Phase III studies for various breast cancer combinations and other tumor types.
Read more
Cardiff Oncology publishes phase 2 trial data for KRAS mutant mCRC
- Phase 2 trial shows onvansertib with FOLFIRI and bevacizumab is effective and well-tolerated in KRAS mutant mCRC.
- Post hoc analysis reveals a 7.7-fold higher clinical benefit in bev-naïve patients with an ORR of 77%.
- Findings support the transition of onvansertib to first-line RAS-mutant mCRC treatment.
- Initial data from the first-line CRDF-004 trial expected in H2 2024.
Read more
Numab Therapeutics initiates phase 1 study of NM32 in solid tumors
- Numab Therapeutics has started a Phase 1 clinical trial for NM32, a tri-specific immuno-oncology therapeutic.
- NM32 targets ROR1 and CD3, with a third domain targeting serum albumin for half-life extension.
- The trial is a dose-escalation study to assess pharmacokinetics, pharmacodynamics, and safety.
- Up to 60 patients with ROR1-overexpressing solid tumors will be enrolled across major US clinical sites.
Read more
Three phase 3 trials of datopotamab deruxtecan-based combinations initiated in patients with advanced nonsquamous non-small cell lung cancer
- Three global phase 3 trials have begun to evaluate datopotamab deruxtecan-based combinations in advanced nonsquamous NSCLC.
- TROPION-Lung10 compares datopotamab deruxtecan plus rilvegostomig or rilvegostomig alone against pembrolizumab in high PD-L1 expressing NSCLC.
- TROPION-Lung14 assesses datopotamab deruxtecan with osimertinib versus osimertinib alone in EGFR mutated NSCLC.
- TROPION-Lung15 evaluates datopotamab deruxtecan with or without osimertinib against platinum-based chemotherapy in EGFR mutated NSCLC post-osimertinib treatment.
Read more
Akeso enrolls first patient in phase 3 trial for head and neck cancer treatment
- Akeso has initiated a Phase III trial (AK117-302) for head and neck squamous cell carcinoma (HNSCC).
- The trial compares ivonescimab and ligufalimab against pembrolizumab for first-line treatment.
- This is the first global Phase III trial investigating a CD47 monoclonal antibody for solid tumors.
- Initial data shows significant tumor reduction and survival benefits for HNSCC patients.
Read more
